This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 1940-6207.CAPR-09-0002v1 2/5/496    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rose-Hellekant, T. A. Articles by Kundel, D. W. Search for Related Content PubMed PubMed Citation Articles by Rose-Hellekant, T. A. Articles by Kundel, D. W. Related Collections Preclinical Intervention Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms Oncogenesis: Animal Models

Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor–Positive/Progesterone Receptor–Negative Mammary Tumors

Authors' Affiliations: Departments of ¹ Physiology and Pharmacology, ² Biochemistry and Molecular Biology, and ³ Pathology and Laboratory Medicine, University of Minnesota Medical School-Duluth Campus, and ⁴ Department of Mathematics and Statistics, University of Minnesota-Duluth, Duluth, Minnesota

Requests for reprints: Teresa A. Rose-Hellekant, Department of Physiology and Pharmacology, University of Minnesota Medical School-Duluth Campus, 1035 University Drive, Duluth, MN 55812. Phone: 218-727-6621; Fax: 218-726-6356; E-mail: trosehel{at}d.umn.edu.

Although many estrogen receptor–positive (ER+) breast cancers are effectively treated with selective estrogen receptor modulators and down-regulators (SERM/SERD), some are highly resistant. Resistance is more likely if primary cancers are devoid of progesterone receptors (PR–) or have high levels of growth factor activity. In this study, a transgenic mouse line that expresses transforming growth factor- (NRL-TGF mice) and that develops ER+/PR– mammary tumors was used to assess the possible effects of (a) therapeutic delivery of the SERM, tamoxifen, or SERD, ICI I82,780 (ICI), on the growth of established tumors and (b) short-term prophylactic tamoxifen administration on the initial development of new mammary tumors. To determine the therapeutic effects of tamoxifen and ICI on the growth of established tumors, mice were exposed to 3 weeks of drug treatment. Neither drug influenced tumor growth or glandular pathology. To determine if early prophylactic tamoxifen could alter tumorigenesis, a 60-day tamoxifen treatment was initiated in 8-week-old mice. Compared with placebo-treated mice, tamoxifen reduced tumor incidence by 50% and significantly decreased the degree of mammary hyperplasia. Prophylactic tamoxifen also significantly extended the life span of tumor-free mice. These data show that in this mouse model, established ER+/PR– mammary tumors are resistant to SERM/SERD treatment but the development of new mammary tumors can be prevented by an early course of tamoxifen. This study validates the utility of NRL-TGF mice for (a) identifying candidate biomarkers of efficacious tamoxifen chemoprevention and (b) modeling the evolution of tamoxifen resistance.

Key Words: Tamoxifen • chemoprevention • breast cancer • TGF • transgenic mice